We are live on ! Find out more
LYEL icon

Lyell Immunopharma
LYEL

62 hedge funds and large institutions have $1.22B invested in Lyell Immunopharma in 2021 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 18

19% more funds holding

Funds holding: 52 → 62 (+10)

0.08% more ownership

Funds ownership: 1.64% → 1.72% (+0.08%)

0% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 11

6% less capital invested

Capital invested by funds: $1.29B → $1.22B (-$72.7M)

25% less funds holding in top 10

Funds holding in top 10: 8 → 6 (-2)

Holders
62
Holders Change
+10
Holders Change %
+19.23%
% of All Funds
1.09%
Holding in Top 10
6
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-25%
% of All Funds
0.11%
New
28
Increased
11
Reduced
11
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BlackRock
BlackRock
New York
+$17.7M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$17.4M
3
HH
HSG Holding
Hong Kong
+$9.13M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$6.94M
5
Brown Advisory
Brown Advisory
Maryland
+$6.84M

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$16.6M
2
ACA
Arena Capital Advisors
California
-$8.85M
3
WP
Woodline Partners
California
-$4.4M
4
Goldman Sachs
Goldman Sachs
New York
-$3.28M
5
MIM
Monashee Investment Management
Massachusetts
-$2.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Victory Capital Management
26
Victory Capital Management
Texas
$3.11M +$255K +852 +9%
WP
27
Woodline Partners
California
$3.05M -$4.4M -14,684 -59%
Citadel Advisors
28
Citadel Advisors
Florida
$2.78M -$2.1M -7,016 -43%
Charles Schwab
29
Charles Schwab
California
$2.46M +$2.49M +8,313 New
IHAM
30
Integral Health Asset Management
New York
$2.07M +$2.1M +7,000 New
Balyasny Asset Management
31
Balyasny Asset Management
Illinois
$1.9M +$1.93M +6,427 New
TD Asset Management
32
TD Asset Management
Ontario, Canada
$1.67M +$392K +1,308 +30%
CCM
33
CAAS Capital Management
New York
$1.48M – – –
EHI
34
Eagle Health Investments
Connecticut
$1.48M – – –
Millennium Management
35
Millennium Management
New York
$970K -$983K -3,282 -50%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$867K +$878K +2,931 New
N
37
Nuveen
North Carolina
$678K +$686K +2,290 New
CSS
38
Cubist Systematic Strategies
Connecticut
$602K +$522K +1,743 +601%
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
$474K +$480K +1,601 New
MCM
40
Moore Capital Management
New York
$438K -$13.2K -44 -3%
Jane Street
41
Jane Street
New York
$295K +$299K +998 New
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$250K +$253K +844 New
GCM
43
Ghisallo Capital Management
Massachusetts
$222K -$1.27M -4,250 -85%
Manulife (Manufacturers Life Insurance)
44
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$222K +$225K +751 New
WMSA
45
Weiss Multi-Strategy Advisers
New York
$218K -$154K -515 -41%
Deutsche Bank
46
Deutsche Bank
Germany
$201K +$204K +680 New
AIG
47
American International Group
New York
$191K +$194K +647 New
California State Teachers Retirement System (CalSTRS)
48
California State Teachers Retirement System (CalSTRS)
California
$189K +$191K +638 New
SG Americas Securities
49
SG Americas Securities
New York
$157K +$159K +531 New
MIM
50
MetLife Investment Management
New Jersey
$153K +$155K +516 New
1
2
3 4

LYEL Hedge Fund Activity: Q3 2021 in Review

62 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q3 2021, worth a combined $1.22B — down 5.6% from $1.29B a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new LYEL positions and 18 closed out — a net gain of 10 holders — while 11 added to existing stakes and 11 trimmed.

The largest buyer was BlackRock, adding an estimated $17.7M. The largest seller was Morgan Stanley, cutting an estimated $16.6M.

  • 62 institutional investors held Lyell Immunopharma (LYEL) as of Q3 2021, up from 52 in Q2 2021.
  • Funds reported $1.22B of Lyell Immunopharma stock for Q3 2021, down 5.6% quarter-over-quarter.
  • 28 funds opened new Lyell Immunopharma positions in Q3 2021 and 18 closed out, a net change of +10 holders.
  • The largest Lyell Immunopharma buyer in Q3 2021 was BlackRock, an estimated $17.7M added.
  • The largest Lyell Immunopharma seller in Q3 2021 was Morgan Stanley, an estimated $16.6M sold.

Based on aggregated 13F filings for Q3 2021.